Latest Protease inhibitor Stories
HUDDINGE, Sweden, April 1, 2011 /PRNewswire-FirstCall/ -- - Results Show Potent Antiviral Efficacy of Once Daily 150 mg TMC435 in Hepatitis C Patients Who Have Failed Earlier Treatment, Especially in Prior Null Responders, and Excellent Safety and Tolerability Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner, Tibotec has presented the results of a planned Week 24 interim analysis of the...
A clinical study of anti-HIV/AIDS medicines in the developing world is on the verge of turning "the whole treatment world on its head," according to Dartmouth pediatrician Paul Palumbo.
HUDDINGE, Sweden, February 18, 2011 /PRNewswire-FirstCall/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started. Phase 3 Program in brief: - TMC435-C208 or QUEST-1 includes approximately 375...
HUDDINGE, Sweden, February 14, 2011 /PRNewswire/ -- Highlights of the Collaboration: - Collaboration with Janssen Pharmaceutica N.V.
HUDDINGE, Sweden, February 10, 2011 /PRNewswire/ -- Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a phase 1a clinical trial with TMC649128 intended for the treatment of chronic hepatitis C virus infection. TMC649128 is a nucleoside NS5B polymerase inhibitor that has already demonstrated an attractive pre-clinical profile.
CAMBRIDGE, Mass., Feb. 9, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced updates to three clinical development programs.
Itâ€™s a well-known fact that children with HIV will need anti-HIV medicines for longer than adults.
New report from MedPredict includes thought leader discussion of key development activities in the HCV pipeline, including their perspectives on unmet needs and how compounds nearing approval are likely to address them.
HUDDINGE, Sweden, November 18, 2010 /PRNewswire/ -- - Once Daily Novel Therapy in Treatment-Experienced Hepatitis C Patients Highlights of the Study TMC435 Added to Standard of Care: - Increased the response rates and antiviral efficacy, which progressed through to week 24 - Increased the number of patients with undetectable Hepatitis C Virus (HCV) levels through week 4, 12 and 24 - Safe and well tolerated Medivir AB (OMX: MVIR), the emerging...
HUDDINGE, Sweden, November 1, 2010 /PRNewswire/ -- Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.